CUL4A facilitates hepatocarcinogenesis by promoting cell cycle progression and epithelial-mesenchymal transition

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Pan, Yingfang ^a,c   Wang, Bo ^a   Yang, Xiaoyun ^b   Bai, Fuxiang ^a   Xu, Qun ^c   Li, Xueen ^b   Gao, Lifen ^a   Ma, Chunhong ^a   Liang, Xiaohong ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c Shandong Blood Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CCNB1 PROTEIN, HUMAN; CUL4A PROTEIN, HUMAN; CULLIN; CYCLIN A; CYCLIN B1; SMALL INTERFERING RNA;

ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER NEOPLASMS; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME;

ADULT; ANIMALS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CULLIN PROTEINS; CYCLIN A; CYCLIN B1; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; NEOPLASM TRANSPLANTATION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR BURDEN;

EID: 84948418267     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17006     Document Type: Article

References (38)

1. Sherman, M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 30, 3-16, doi: 10.1055/s-0030-1247128 (2010).
2. Aravalli, R. N., Steer, C. J. & Cressman, E. N. Molecular mechanisms of hepatocellular carcinoma. Hepatology 48, 2047-2063, doi: 10.1002/hep.22580 (2008).
3. Nishida, N. & Goel, A. Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr Genomics 12, 130-137, doi: 10.2174/138920211795564359 (2011).
4. Liu, M., Jiang, L. & Guan, X. Y. The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update. Protein Cell 5, 673-691, doi: 10.1007/s13238-014-0065-9 (2014).
5. Yasui, K. et al. TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology 35, 1476-1484, doi: 10.1053/jhep.2002.33683 (2002).
6. Hori, T. et al. Covalent modification of all members of human cullin family proteins by NEDD8. Oncogene 18, 6829-6834, doi: 10.1038/sj.onc.1203093 (1999).
7. Sharma, P. & Nag, A. CUL4A ubiquitin ligase: a promising drug target for cancer and other human diseases. Open Biol 4, 130217, doi: 10.1098/rsob.130217 (2014).
8. Shinomiya, T. et al. Comparative genomic hybridization of squamous cell carcinoma of the esophagus: the possible involvement of the DPI gene in the 13q34 amplicon. Genes Chromosomes Cancer 24, 337-344 (1999).
9. Dohna, M. et al. Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes Cancer 28, 145-152 (2000).
10. Birner, P. et al. Human homologue for Caenorhabditis elegans CUL-4 protein overexpression is associated with malignant potential of epithelial ovarian tumours and poor outcome in carcinoma. J Clin Pathol 65, 507-511, doi: 10.1136/ jclinpath-2011-200463 (2012).
11. Xu, Y., Wang, Y., Ma, G., Wang, Q. & Wei, G. CUL4A is overexpressed in human pituitary adenomas and regulates pituitary tumor cell proliferation. J Neurooncol 116, 625-632, doi: 10.1007/s11060-013-1349-2 (2014).
12. Chen, L. C. et al. The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers. Cancer Res 58, 3677-3683 (1998).
13. Schindl, M., Gnant, M., Schoppmann, S. F., Horvat, R. & Birner, P. Overexpression of the human homologue for Caenorhabditis elegans cul-4 gene is associated with poor outcome in node-negative breast cancer. Anticancer Res 27, 949-952 (2007).
14. Wang, Y. et al. CUL4A overexpression enhances lung tumor growth and sensitizes lung cancer cells to Erlotinib via transcriptional regulation of EGFR. Mol Cancer 13, 252, doi: 10.1186/1476-4598-13-252 (2014).
15. Wang, Y. et al. CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res 74, 520-531, doi: 10.1158/0008-5472.CAN-13-2182 (2014).
16. Wang, Y. et al. Involvement of CUL4A in regulation of multidrug resistance to P-gp substrate drugs in breast cancer cells. Molecules 19, 159-176, doi: 10.3390/molecules19010159 (2013).
17. Sanyal, A. J., Yoon, S. K. & Lencioni, R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 15, Suppl 4, 14-22, doi: 10.1634/theoncologist.2010-S4-14 (2010).
18. Yim, H. J. & Lok, A. S. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 43, S173-181, doi: 10.1002/hep.20956 (2006).
19. van Zijl, F. et al. Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol 5, 1169-1179, doi: 10.2217/ fon.09.91 (2009).
20. Arzumanyan, A., Reis, H. M. & Feitelson, M. A. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 13, 123-135, doi: 10.1038/nrc3449 (2013).
21. Hung, M. S. et al. Cul4A is an oncogene in malignant pleural mesothelioma. J Cell Mol Med 15, 350-358, doi: 10.1111/j.1582-4934.2009.00971.x (2011).
22. Jiang, L., Rong, R., Sheikh, M. S. & Huang, Y. Cullin-4A.DNA damage-binding protein 1 E3 ligase complex targets tumor suppressor RASSF1A for degradation during mitosis. J Biol Chem 286, 6971-6978, doi: 10.1074/jbc.M110.186494 (2011).
23. Rosenblatt, J., Gu, Y. & Morgan, D. O. Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A. Proc Natl Acad Sci USA 89, 2824-2828 (1992).
24. Pines, J. & Hunter, T. Human cyclins A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport. J Cell Biol 115, 1-17 (1991).
25. Park, T. J. et al. TIS21 negatively regulates hepatocarcinogenesis by disruption of cyclin B1-Forkhead box M1 regulation loop. Hepatology 47, 1533-1543, doi: 10.1002/hep.22212 (2008).
26. Wang, L. H., Huang, W., Lai, M. D. & Su, I. J. Aberrant cyclin A expression and centrosome overduplication induced by hepatitis B virus pre-S2 mutants and its implication in hepatocarcinogenesis. Carcinogenesis 33, 466-472, doi: 10.1093/carcin/bgr296 (2012).
27. Ogunwobi, O. O. & Liu, C. Therapeutic and prognostic importance of epithelial-mesenchymal transition in liver cancers: insights from experimental models. Crit Rev Oncol Hematol 83, 319-328, doi: 10.1016/j.critrevonc.2011.11.007 (2012).
28. Thompson, E. W., Newgreen, D. F. & Tarin, D. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 65, 5991-5995; discussion 5995, doi: 10.1158/0008-5472.CAN-05-0616 (2005).
29. Edmondson, H. A. & Steiner, P. E. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7, 462-503 (1954).
30. Han, C. P. et al. Scoring of p16(INK4a) immunohistochemistry based on independent nuclear staining alone can sufficiently distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. Mod Pathol 22, 797-806, doi: 10.1038/modpathol.2009.31 (2009).
31. Kamoi, S., AlJuboury, M. I., Akin, M. R. & Silverberg, S. G. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint. Int J Gynecol Pathol 21, 217-223 (2002).
32. Han, C. P. et al. Nuclear Receptor Interaction Protein (NRIP) expression assay using human tissue microarray and immunohistochemistry technology confirming nuclear localization. J Exp Clin Cancer Res 27, 25, doi: 10.1186/1756-9966-27-25 (2008).
33. Yan, W. et al. Tim-3 fosters HCC development by enhancing TGF-beta-mediated alternative activation of macrophages. Gut 64, 1593-1604, doi: 10.1136/gutjnl-2014-307671 (2015).
34. Li, X. et al. Cullin 4B protein ubiquitin ligase targets peroxiredoxin III for degradation. J Biol Chem 286, 32344-32354, doi: 10.1074/jbc.M111.249003 (2011).
35. Du, J. et al. Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression. Cell Death Differ 16, 219-229, doi: 10.1038/cdd.2008.144 (2009).
36. Liang, X. et al. Hepatitis B virus sensitizes hepatocytes to TRAIL-induced apoptosis through Bax. J Immunol 178, 503-510 (2007).
37. Luan, F. et al. Hepatitis B virus protein preS2 potentially promotes HCC development via its transcriptional activation of hTERT. Gut 58, 1528-1537, doi: 10.1136/gut.2008.174029 (2009).
38. Gai, X. et al. Hepatitis B virus core protein enhances human telomerase reverse transcriptase expression and hepatocellular carcinoma cell proliferation in a c-Ets2-dependent manner. Int J Biochem Cell Biol 45, 1174-1185, doi: 10.1016/j.biocel.2013.03.015 (2013).